NYCELLO Intent to Use Trademark Application for Cell Therapy
Summary
The USPTO has received an intent-to-use trademark application for the mark NYCELLO. The application covers various cell therapy and immunotherapy preparations and related medical treatment services. The filing date was April 25, 2025.
What changed
The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99155713) for the mark NYCELLO. The application covers a range of goods and services, including cell therapy pharmaceutical preparations, immunotherapy preparations for cancer treatment, T-cell receptors, and medical services related to cell therapy and immunotherapy. The filing date for this application was April 25, 2025.
This filing represents a new potential brand entry into the cell therapy and immunotherapy market. While this is a trademark application and not a regulatory approval for the therapy itself, it indicates a commercial intent for these specific medical products and services. Companies operating in the cell therapy space should be aware of this new trademark filing as it may impact branding and market positioning in the future.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
NYCELLO
Intent to Use TM99155713 Kind: intenttouse Mar 24, 2026
Abstract
Cell therapy pharmaceutical preparations; immunotherapy preparations for use in cancer treatment; T-cell receptors in the nature of pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment; Cell therapy medical treatment services; medical services, namely, immunotherapy services; medical services, namely, medical treatment and immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient
Filing Date
2025-04-25
Related changes
Get daily alerts for USPTO Trademarks - Medical Services (Class 044)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Medical Services (Class 044) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.